Spruce Biosciences, Inc. (OTC: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant ...

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced a license agreement ...

For example, Cytek Biosciences, Inc. (NASDAQ:CTKB), which develops products for cell analysis in biomedical research, reported headwinds from NIH funding reductions, new export controls for flow ...

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ ...

In trading on Thursday, shares of Harmony Biosciences Holdings Inc (Symbol: HRMY) crossed below their 200 day moving average of $34.67, changing hands as low as $34.50 per share. Harmony ...

TriLink BioTechnologies®, a division of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), announced a non-exclusive License and Supply Agreement with Quantoom Biosciences on June 3, 2025.

The state’s bioscience industry was celebrating Wednesday after lawmakers approved a $55.8 billion, two-year budget that includes expanding the state’s research and development tax credit.

Cellectar Biosciences, Inc. CLRB stock is trading higher on Wednesday. As per data from Benzinga Pro, session volume stands at 361.96 million versus an average volume of 968.03k .

Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne. The stock jumped 42%, to ...

(RTTNews) - Sagimet Biosciences (SGMT) reported that denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted ...